Peter Andrews is an Honorary Professor at the University of Edinburgh, from August 1, 2007. He has an international reputation in Neurological Intensive Care and has sustained an active, externally funded research programme for more than twenty years.
Research streams include; “Direct Brain Cooling” studies attracting external funding of over £350K and public recognition of the importance of this work. This work has lead to grant funding to develop non-invasive measurement of regional brain temperature using magnetic resonance spectroscopy.
Prof. Andrews is the Chief Investigator of the EUROTHERM3235Trial investigating the use of titrated (www.eurotherm3235trial.eu) hypothermia after traumatic brain injury in patients with raised intracranial pressure. This has attracted funding of £900K from the European Society of Intensive Care Medicine for the pilot phase and the National Institute for Health, Health Technology Assessment board recently (September 2012) awarded £2.18Million for main phase of the trial.
Prof Andrews was the Chief Investigator of the “SIGNET Trial” (RCT in Scottish Intensive Care Units). This was the first UK non-commercial multicentre CT-IMP trial in critical care and had funding of over £1.5M (including £1.1M from the MRC, UK).
Prof Andrews is chairman of the VANISH and TOPSAT2 Trials DMCs and a member of another 4 DSMBs. Prof Andrews is section head for Neurological-Intensive Care (Europe) at Faculty of Medicine 1000 (http://www.facultyof1000.com) and member of the Scottish Neuroscience Council.